Artrocol (ketoprofen) gel 25 mg/g. 45 g. tube №1

active ingredient: ketoprofen;

1 g of gel contains ketoprofen 25 mg;

excipients: carbomer 980, triethanolamine, ethanol 96%, methyl paraben (E 218), purified water.

Gel.

Basic physical and chemical properties: homogeneous transparent gel.

Non-steroidal anti-inflammatory drugs for topical use. ATX code M02A A10.

Ketoprofen belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDs), arylpropionic acid derivatives. It has an analgesic and anti-inflammatory effect due to inhibition of the action of cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2) and bradykinin, stabilization of lysosomal membranes and inhibition of macrophage migration. Ketoprofen has analgesic and anti-inflammatory activity both at an early stage (vascular phase) and at a late stage (cellular phase) of the inflammatory reaction, and also inhibits platelet aggregation.

When applied topically, ketoprofen is absorbed from the skin, penetrates locally into inflamed tissues and maintains a therapeutic concentration in them for a long time. Absorption to the systemic circulation is very low (only 5% of the dose) and is slow. When applied to the skin of a gel containing from 50 to 150 mg of ketoprofen, the concentration of the active substance in the blood plasma after 5-8 hours is no more than 0.08-0.15 μg / ml, practically does not have a clinically significant effect on the body.

Muscle and joint pain caused by injury or damage. Tendovaginitis.

• Hypersensitivity reactions are known, for example, symptoms of bronchial asthma, allergic rhinitis, which occurred with the use of dexketoprofen, ketoprofen, fenofibrate, thiaprofenic acid, acetylsalicylic acid or other NSAIDs.
• Hypersensitivity to other components of the drug.
• Any history of photosensitivity.
• A history of skin manifestations of allergy when using dexketoprofen, ketoprofen, thiaprofenic acid, fenofibrate, ultraviolet (UV) blockers, or perfumes.
• Exposure to sunlight (even diffused light) or UV exposure in a solarium during treatment with the drug and within 2 weeks after stopping its use.
• Use in the presence of pathological changes on the skin, such as weeping dermatoses, skin lesions, rashes, skin injuries, burns, eczema or acne, or infectious processes of the skin and open wounds.
• III trimester of pregnancy.